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patients who begin with low and high levels and regardless of
ﬁnal level achieved. METHODS: A cohort of 27,660 patients
with coronary artery disease, peripheral vascular disease, or dia-
betes mellitus were selected and followed retrospectively for their
ﬁrst myocardial infarction or revascularization recorded in 
the New England Veterans Affairs database. Pre-outcome 
low-density lipoprotein cholesterol reduction was categorized as
follows: <10 mg/dl, reference; 10–39 mg/dl, small reduction;
40–69 mg/dl, moderate reduction; >70 mg/dl, large reduction.
Cox proportional hazards was used to determine hazard ratios
for each category of lipid reduction compared to reference and
stratiﬁed by high or low initial LDL-C, adjusting for initial LDL-
C, statin use, age, gender, and co morbidities. RESULTS: Among
patients with initial LDL-C above the median of 133 mg/dL,
hazard ratios (95% conﬁdence intervals) for small, moderate,
and large reductions compared to reference were 0.90
(0.85–0.96), 0.84 (0.79–0.90), and 0.76 (0.70–0.83) respectively.
A total of 3448 or 24% of such patients achieved a ﬁnal level
<100 mg/dL. Among patients with initial levels below the
median, hazard ratios (95% conﬁdence intervals) for small, 
moderate, and large reductions were 0.90 (0.85–0.96), 0.87
(0.79–0.96), and 0.76 (0.56–1.05) respectively. A total of 5492
or 40% of such patients achieved ﬁnal level <100 mg/dL. CON-
CLUSION: These data suggest that magnitude of reduction in
low-density lipoprotein cholesterol is proportional to degree of
reduction in cardiovascular risk, and that this effect holds both
for patients with initially low or high lipid levels, regardless of
whether a ﬁnal LDL-C of <100 mg/dL was achieved.
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OBJECTIVES: The lipid-lowering arm of ASCOT demonstrated
that in hypertensive patients, in primary prevention who are not
conventionally deemed dyslipidaemic and with at least three car-
diovascular risk factors (CVRF), atorvastatin ten mg conferred
a reduction in CV morbimortality. There are no data regarding
the prevalence of these patients among the hypertensives in
Spain. The objective is to determine the prevalence of the patient
as deﬁned in the ASCOT among the Spanish hypertensives.
METHODS: Data from 2004 to 2005 of 6309 hypertensives
from Spanish primary care centres were studied. We analyzed the
following variables: left-ventricular hypertrophy, other speciﬁed
abnormalities on EKG, type 2 diabetes, peripheral arterial
disease, previous stroke, gender, age, microalbuminuria,
smoking, ratio total cholesterol/HDL-cholesterol, and premature
family history of CHD. We analyzed the Number of CVRF as
deﬁned in ASCOT and the percentage of patients with CVRF ≥3
(with normal TC and in primary prevention). RESULTS: Of the
6309 patients, 2528 (40%) had history of CHD and/or heart
failure and/or TC >250 mg/dl and/or a statin treatment. The
presence of ASCOT-CVFR ≥3 was analyzed in the 3781 remain-
ing ones. The percentage of additional CVRF relative to these
3781 patients was: 0 FRCV: 4.3%; 1 FRCV: 24.6%; 2 FRCV:
30.4%; 3 FRCV: 22.2%; 4 FRCV: 11.8%; 5FRCV: 5.1%; 6
FRCV: 1.3%; 7 FRCV: 0.3%; 8 FRCV: 0.03%. There were 1540
patients (40.7%) with CVRF ≥3. This percentage, in relation to
the whole population of hypertensives (6309) was 24.4%. CON-
CLUSIONS: Because of the retrospective nature of the design, it
is advisable to be prudent in the external generalization. Never-
theless a high prevalence (at least 40.7%) of the ASCOT-patient
(CVRF ≥3), relative to a population of Spanish hypertensive
patients in primary prevention, not treated with statins and with
total cholesterol ≤250 mg/dL, have been demonstrated.
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OBJECTIVE: The ALLHAT study, published in December of
2002, indicated improved outcomes for hypertensive patients on
thiazide diuretics. This study evaluated the utilization of thi-
azides in hypertensives in the year before and after the publica-
tion of these results in a national primary care database.
METHODS: A retrospective review of an electronic medical
record (EMR) database (GE Medical Systems Centricity) con-
taining the ambulatory health record data for over 3.2 million
individuals was conducted. Patients with an ICD-9 code for
hypertension (HPTN) and a GPI code for thiazide diuretic were
identiﬁed in calendar years 2002 and 2003. Patients in each year
on thiazides, on or after HPTN diagnosis, were taken as a per-
centage of those with hypertension. RESULTS: In the year 2002
there were 81,916 patients with hypertension, 40,392 patients
on thiazide diuretics and 17,520 patients with both. Of those,
15,253 had their thiazide prescription on or after the date of
HPTN diagnosis. In 2003 there were 114,347 patients with
HPTN, 56,796 on thiazides, 26,199 with HPTN and 22,321
with their thiazide prescription on or after HPTN diagnosis. The
percent of hypertensives on thiazides was 18.62% in 2002 and
19.52% in 2003 with an increase of 0.9% in thiazide use in
patients with hypertension. CONCLUSION: Despite published
evidence of improved outcomes for hypertensive patients treated
with thiazide diuretics, the increase utilization in a primary care
database was modest.
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OBJECTIVES: To determine the association and The rapeutic
control goals of certain cardiovascular risk factors (CVRF) in a
Spanish primary care population. METHODS: A retrospective
study was performed based on patient’s data from ﬁve ambula-
tory primary care centres. Patients aged >18 years, attended
during year 2004, with at least one major CVRF were included.
The following variables were analysed: age, sex, main diagnosis
(hypertension, dyslipidemia, diabetes and/or cardiovascular
event [ECV]) and clinical parameters (systolic blood pressure,
diastolic blood pressure, LDLc, HbA1c). Therapeutic control
goals were established according to NCEP-ATP III. A bivariant
analysis and a binary logistic regression model were performed
to ﬁt the model. The statistical program SPSS was used with a
5% signiﬁcance level. RESULTS: A total of 15,470 patients had
at least one CVRF. Mean age was 61.3 ± 14.3; 53.7% were
female and 14.2% had a history of CVD. The diagnosis was
hypertension in 60.6%, diabetes in 26.7% and hipercoles-
terolemia in 49.5%. The presence of CVRF >3 was conﬁrmed in
5.8% and CVD in 28.3%. The percentage of patients who
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uncontroled BP or TC was 46.4% and 48.7%, respectively. The
correction of the logistic model demonstrated the association of
CVD with male sex (OR = 2.6), diabetes (OR = 2.2), dyslipi-
demia (OR = 1.6), BP (OR = 1.3) and age (OR = 1.1), p < 0.05.
CONCLUSIONS: Therapeutic control goals in primary care
setting might be improved. It would be necessary to make new
representative studies showing the degree of control of our
patients in daily clinical practice.
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OBJECTIVES: A recent Pan-European Survey highlighted a
prevalence of low High Density Lipoprotein-cholesterol (HDL-c
<1.03 mmol/L in men and <1.29 mmol/l in women) in over 30%
of patients diagnosed with dyslipidemia, irrespective of statin
treatment. In order to help physicians focus their attention on
this risk factor, a model was used to project clinical beneﬁts on
coronary heart disease (CHD) endpoints of raising HDL-c by
adding Niaspan® to statin therapy in Type 2 Diabetes (T2D)
patients. METHODS: A computer model simulated the clinical
beneﬁt of combination therapy statin + Niaspan®; the ﬁrst sub-
model (Monte-Carlo simulation) generated a cohort using
patient characteristics from the Pan-European Survey (diabetic
sub-group) and applied Niaspan® treatment effect (European
SPC, 2 g/day); the second sub-model (Markov) estimated the
long-term clinical outcomes associated with patient’s lipid
changes (Framingham risk equations). Simulations were run to
capture 5, 10 years and patients’ lifetimes. RESULTS: In these
patients, mean life expectancies of 19.42 years and 18.78 years
were projected for the statin + Niaspan® and statin monother-
apy arms respectively (difference of 0.64 years). The addition of
Niaspan® to statin treatment was associated with a lower cumu-
lative incidence of CHD events than statin monotherapy at dif-
ferent time horizons leading to absolute risk reductions of 14.1%
for myocardial infarction and 5.5% for CHD death. CON-
CLUSIONS: Due to its positive effect on HDL-c levels, the addi-
tion of Niaspan® to statin treatment was projected to reduce 
the cumulative incidence of CHD events compared to statin
monotherapy in a European T2D patient population with per-
sistently low HDL-c.
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OBJECTIVES: Thiazolidinedione (TZD) was recommended not
for patients with moderate and serious heart failures due to the
adverse reaction of body ﬂuid retention. Our study investigated
the use of TZD by type 2 diabetic patients after they were dis-
charged from hospitalizations for heart failure. METHODS: The
cohort observation was based on claims database of Taiwan’s
National Health Insurance (NHI) for 2002∼2004. There were
4774 diabetic patients who were hospitalized due to heart failure
during 2003: 379 TZD users and 4395 non-TZD users. A total
of 2692 non-TZD users who used sulfonylurea after discharge
were selected as the control group. Cox proportional hazard
models were estimated to compared the outcomes of death and
readmission to hospitals of TZD users and sulfonylurea users,
one year after the time patients were discharged. RESULTS:
There were 7.9% of diabetic patients who were hospitalized for
heart failure and received TZD treatments. There was no signif-
icant difference on readmission over one year after discharge
between the two groups. However, among those who used TZD
or sulfonylurea less than 60 days, those who used TZD had
lower HR of readmission than those who used sulfonylurea (HR
0.728, 95% CI 0.551∼0.962). Overall, the HR for death among
patients receiving TZD was signiﬁcant lower than the control
group of sulfonylurea users (HR 0.092, 95% CI = 0.022–0.380).
CONCLUSIONS: Based on the precautions stated in TZD
package inserts, 7.9% of type 2 diabetic patients with heart
failure received potentially inappropriate prescriptions. Short
term use of TZD signiﬁcantly reduced hazards ratio in readmis-
sion, though long term use of both TZD and sulfonylurea
showed no difference on readmission, and the use of TZD sig-
niﬁcantly reduced the hazard of death.
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OBJECTIVES: Changing patterns of immunosuppression use
have been associated with increased risk of adverse graft and
patient survival outcomes. This study aimed to assess the rela-
tionship between discontinuing use of mycophenolate mofetil
(MMF) on two-year graft loss and two-year patient death.
METHODS: US claims data from commercial health plans for
396 patients receiving heart transplants (1995–2005) were
linked to data from the Organ Procurement Transplant Network
(OPTN). Transplant recipients were grouped into two: those
who continued and those who discontinued (MMF DC) using
MMF. MMF use was deﬁned as having ≥1 pharmacy claim post-
transplant for the medication. Discontinuation was deﬁned as
more than a 30 day gap in MMF coverage followed by no sub-
sequent reﬁlls during the year following the initial MMF script.
Cox proportional hazards analysis was used to estimate the risk
of discontinuing MMF on graft loss and dying. RESULTS: Thir-
teen percent (N = 52) of the study population was in the MMF
DC group. The majority of the population was between age 41
and 60 (57%), male (78%), transplanted between 1996–2000
(44%), and received a medication for a gastrointestinal condi-
tion during the year following their initial MMF script (65%).
Discontinuing use of MMF was associated with an increased risk
of graft loss (Hazard Ratio [HR] = 3.45 p = 0.04) and an
increased risk of death (HR = 2.79, p = 0.01) compared to con-
tinued MMF use during the year of follow-up. CONCLUSIONS:
Disrupting the pattern of MMF use was related to a signiﬁcant
increase in the risk of graft loss and death during two years post
transplant in this heart transplant recipient population covered
by commercial health plans. Future work should examine
whether these ﬁndings extend to heart transplant recipients
covered by other types of insurance and potential causes of
therapy discontinuation.
